Is a Biopsy Required to Classify Patients with Idiopathic Retroperitoneal Fibrosis as IgG4-RPF or Non-IgG4-RPF?
Aktuelle Rheumatologie · 01.04.2025 · 50 (02) · 126-133
DOI: 10.1055/a-2321-1674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aktuelle Rheumatologie, erschienen am 01.04.2025. Verfasst von Salim Misirci und 7 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
Our aim was to group cases of idiopathic retroperitoneal fibrosis (IRPF) into those associated with immunoglobulin (Ig) G4-related disease (IgG4-RD) (IgG4-RPF) and those not associated with IgG4-RD (non-IgG4-RPF) and to compare the clinical presentation, laboratory findings, imaging, and treatment methods.
Methods
A total of 46 patients were included in the study. According to the assessment by two experienced rheumatologists and the IgG4-RPF classification criteria published by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) in 2019, 11 patients who were admitted as IgG4-RPF were included in the IgG4-RPF group and 35 patients who were not admitted as IgG4-RPF were included in the non-IgG4-RPF group. The clinical and demographic characteristics, affected sites, laboratory results and treatments were retrospectively evaluated and compared.
Results
The mean age of our patients was 50.69 (±11.33) in the non-IgG4-RPF group and 55.36 (±7.80) in the IgG4-RPF group and was similar in both groups (p=0.340). The male gender dominated in both groups. Although there was no significant difference between the groups in terms of acute renal failure (p=0.074), this was more frequent in the IgG4-RPF group (81.82%). An increased IgG4 concentration was found in about half (n=6, 54.55%) of the patients in the IgG4-RPF group, while this was present in only 5.71% (n=2) of the patients in the non-IgG4-RPF group (p=0.001). The most commonly used diagnostic imaging modality was computed tomography. Biopsy was performed in almost all patients (n=10, 90.91%) in the IgG4-RPF group and 11 (31.43%) in the non-IgG4-RPF group (p0.05).
Conclusion
IRPF can present with similar clinical and imaging findings in IgG4-RPF and non-IgG4-RPF groups. Since a similar treatment success can be achieved in both groups with similar therapeutic agents, we believe that a biopsy is not necessary in patients with an uncertain diagnosis of IRPF.
Zitieren
APA
Misirci, S., Ekin, A., Coskun, B. N., Yagız, B., Yılmaz, Ö., Yıldız, A., Dalkılıç, E., & Pehlivan, Y. (2025). Is a Biopsy Required to Classify Patients with Idiopathic Retroperitoneal Fibrosis as IgG4-RPF or Non-IgG4-RPF?. Aktuelle Rheumatologie, 50(02), 126-133. https://doi.org/10.1055/a-2321-1674
Vancouver
Misirci S, Ekin A, Coskun BN, Yagız B, Yılmaz Ö, Yıldız A, et al. Is a Biopsy Required to Classify Patients with Idiopathic Retroperitoneal Fibrosis as IgG4-RPF or Non-IgG4-RPF?. Aktuelle Rheumatologie. 2025;50(02):126-133. doi:10.1055/a-2321-1674
BibTeX
@article{Misirci2025,
author = {Misirci, Salim and Ekin, Ali and Coskun, Belkis Nihan and Yagız, Burcu and Yılmaz, Özgür and Yıldız, Abdulmecit and Dalkılıç, Ediz and Pehlivan, Yavuz},
title = {Is a Biopsy Required to Classify Patients with Idiopathic Retroperitoneal Fibrosis as IgG4-RPF or Non-IgG4-RPF?},
journal = {Aktuelle Rheumatologie},
year = {2025},
volume = {50},
number = {02},
pages = {126--133},
doi = {10.1055/a-2321-1674}
}
EUVIMED